Trial · NCT00601835
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants ≥ 60 Years of Age With Antibody Levels ≥ 0.10 IU/mL to Tetanus and Diphtheria. | Canadian Td Vaccine Group | Tetanus Post-vaccination Seroprotection | 96 | Percentage of participants | |
| Percentage of Participants ≥ 60 Years of Age With Antibody Levels ≥ 0.10 IU/mL to Tetanus and Diphtheria. | United States Td Vaccine Group | Tetanus Post-vaccination Seroprotection | 97 | Percentage of participants | |
| Percentage of Participants ≥ 60 Years of Age With Antibody Levels ≥ 0.10 IU/mL to Tetanus and Diphtheria. | Canadian Td Vaccine Group | Diphtheria Post-vaccination Seroprotection | 71 | Percentage of participants | |
| Percentage of Participants ≥ 60 Years of Age With Antibody Levels ≥ 0.10 IU/mL to Tetanus and Diphtheria. | United States Td Vaccine Group | Diphtheria Post-vaccination Seroprotection | 71 | Percentage of participants | |
| Percentage of Participants ≥ 60 Years of Age With Antibody Levels ≥ 0.10 IU/mL to Tetanus and Diphtheria. | Canadian Td Vaccine Group | Tetanus Booster Response | 82 | Percentage of participants | |
| Percentage of Participants ≥ 60 Years of Age With Antibody Levels ≥ 0.10 IU/mL to Tetanus and Diphtheria. | United States Td Vaccine Group | Tetanus Booster Response | 84 | Percentage of participants | |
| Percentage of Participants ≥ 60 Years of Age With Antibody Levels ≥ 0.10 IU/mL to Tetanus and Diphtheria. | Canadian Td Vaccine Group | Diphtheria Booster Response | 66 | Percentage of participants | |
| Percentage of Participants ≥ 60 Years of Age With Antibody Levels ≥ 0.10 IU/mL to Tetanus and Diphtheria. | United States Td Vaccine Group | Diphtheria Booster Response | 63 | Percentage of participants | |
Post-vaccination Geometric Mean Titer (GMT) to Tetanus and Diphtheria in Participants ≥ 60 Years Vaccinated With Canadian-manufactured or US-manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine. | Canadian Td Vaccine Group | Tetanus post-vaccination | 6.83 | 95% Confidence Interval 6.01 to 7.77 | Titers |
Post-vaccination Geometric Mean Titer (GMT) to Tetanus and Diphtheria in Participants ≥ 60 Years Vaccinated With Canadian-manufactured or US-manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine. | United States Td Vaccine Group | Tetanus post-vaccination | 7.35 | 95% Confidence Interval 6.54 to 8.26 | Titers |
Post-vaccination Geometric Mean Titer (GMT) to Tetanus and Diphtheria in Participants ≥ 60 Years Vaccinated With Canadian-manufactured or US-manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine. | Canadian Td Vaccine Group | Diphtheria post-vaccination | 0.459 | 95% Confidence Interval 0.371 to 0.567 | Titers |
Post-vaccination Geometric Mean Titer (GMT) to Tetanus and Diphtheria in Participants ≥ 60 Years Vaccinated With Canadian-manufactured or US-manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine. | United States Td Vaccine Group | Diphtheria post-vaccination | 0.409 | 95% Confidence Interval 0.332 to 0.504 | Titers |
| Number of Participants Reporting Solicited Injection Site and Systemic Reactions Post-vaccination With Canadian-Manufactured or US-Manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine. | Canadian Td Vaccine Group | Any Injection site pain | 832 | Participants | |
| Number of Participants Reporting Solicited Injection Site and Systemic Reactions Post-vaccination With Canadian-Manufactured or US-Manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine. | United States Td Vaccine Group | Any Injection site pain | 209 | Participants | |
| Number of Participants Reporting Solicited Injection Site and Systemic Reactions Post-vaccination With Canadian-Manufactured or US-Manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine. | Canadian Td Vaccine Group | Grade 3 Injection site pain (require medical care) | 7 | Participants | |
| Number of Participants Reporting Solicited Injection Site and Systemic Reactions Post-vaccination With Canadian-Manufactured or US-Manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine. | United States Td Vaccine Group | Grade 3 Injection site pain (require medical care) | 5 | Participants | |
| Number of Participants Reporting Solicited Injection Site and Systemic Reactions Post-vaccination With Canadian-Manufactured or US-Manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine. | Canadian Td Vaccine Group | Any Injection site redness | 299 | Participants | |
| Number of Participants Reporting Solicited Injection Site and Systemic Reactions Post-vaccination With Canadian-Manufactured or US-Manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine. | United States Td Vaccine Group | Any Injection site redness | 132 | Participants | |
| Number of Participants Reporting Solicited Injection Site and Systemic Reactions Post-vaccination With Canadian-Manufactured or US-Manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine. | Canadian Td Vaccine Group | Grade 3 Injection site redness (≥ 50 mm) | 28 | Participants | |
| Number of Participants Reporting Solicited Injection Site and Systemic Reactions Post-vaccination With Canadian-Manufactured or US-Manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine. | United States Td Vaccine Group | Grade 3 Injection site redness (≥ 50 mm) | 20 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00601835/results